Glaukos at Wells Fargo conference: launch ramps, reimbursement risks

Glaukos reported Epioxa revenue of $11 million in its first full commercial quarter and approximately $20 million of sequential iDose growth in Q2, while maintaining 2024 iDose guidance of $275 million-$280 million. Management expects positive EPS beginning in Q4 2024, citing high-margin franchises, revenue growth outpacing operating expenses, and a long-term path to 30%-40% operating margins. Near-term risks center on Epioxa reimbursement delays after the July J-code rollout and an opaque potential Medicare LCD decision for iDose, which could disrupt growth despite management's unchanged long-term outlook.

Analysis

GKOS is now priced as a successful two-franchise launch story, leaving little tolerance for a reimbursement-driven deceleration. The key near-term issue is not clinical adoption but conversion of prescriptions into paid treatment; prolonged adjudication raises patient/physician abandonment risk and shifts revenue recognition to later quarters. The unusually large gross-to-net burden also means reported revenue can lag procedure demand and makes incremental payer concessions disproportionately damaging to estimates despite high stated gross margins.

A restrictive iDose coverage decision would matter more through utilization disruption than through permanent market loss: sales-force productivity, physician workflow and procedure scheduling can all reset quickly, while recovery takes multiple quarters. That creates a 1-3 month binary-policy window in which GKOS’s premium multiple is vulnerable to estimate cuts, even if the 6-18 month franchise thesis remains credible. Positive EPS is therefore a lower-quality catalyst than it appears: management can preserve earnings by moderating launch investment, but that would weaken the growth-duration narrative supporting the valuation.

The underappreciated competitive read-through is TARS. A successful transdermal entrant could expand demodex diagnosis and validate a larger treatment pool, but it also raises the cost of category education and could force commercial spending before GKOS has demonstrated differentiation. Conversely, weak early iLution data would reinforce TARS’s first-mover advantage and remove a pipeline optionality component from GKOS. The contrarian view is that the more actionable trade is not chasing a screening-device-led demand inflection; screening expands the funnel only if reimbursement throughput and specialist capacity improve simultaneously.

Key Decisions for Investors

• Maintain a tactical underweight/short bias in GKOS into any final iDose coverage determination over the next 1-3 months; use defined-risk put spreads rather than outright short exposure given the possibility of a favorable policy revision. Thesis is falsified by a final policy preserving broad access plus subsequent guidance reaffirmation or upward revision.
• Do not add to GKOS on early Epioxa prescription or screening-placement metrics alone. Upgrade only after two consecutive quarters show paid-eye conversion improving and gross-to-net remaining stable; those data are required to distinguish a temporary claims backlog from structurally weak payer economics.
• Monitor TARS as a relative long versus GKOS only if GKOS's demodex program advances with convincing clinical data and commercial differentiation remains unproven. A GKOS/TARS pair is premature before data; TARS is favored if category growth persists while its market share and payer access remain durable.
• For existing GKOS longs, reduce exposure into policy-event strength and re-enter only after the coverage language, affected patient eligibility, and resulting management guidance are quantified. The risk/reward is asymmetric because a favorable outcome is substantially reflected in a premium growth valuation, while an adverse outcome can trigger both revenue-estimate and multiple compression.